Pharmacy Times
NOVEMBER 8, 2024
Though both vaccines remain effective at preventing severe illness, Moderna’s mRNA-1273.222 vaccine was found to be significantly more effective among adults with underlying medical conditions.
Fierce Pharma
NOVEMBER 8, 2024
A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be in the works from Korea’s Alteogen following a licensing deal worth up to | Alteogen will use its human hyaluronidase hybridization platform to develop a subcutaneous formulation of the blockbuster antibody-drug conjugate.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
NOVEMBER 8, 2024
The drug is being investigated for its potential to reduce fibrosis associated with muscular dystrophy that can cause scarring of the heart tissue.
pharmaphorum
NOVEMBER 8, 2024
Eisai has scaled down its sales expectations for Alzheimer's disease drug Leqembi after sluggish sales growth in the first half of the current fiscal year.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
NOVEMBER 8, 2024
Joel Ferre, JD, Assistant United States Attorney in Utah, led a discussion covering the DEA and pharmacies’ roles in reporting red flags when dispensing medication.
STAT
NOVEMBER 8, 2024
WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
NOVEMBER 8, 2024
I am standing in front of my bathroom mirror trying to control my breathing. It is the morning after the election, and I learned the results when I woke about one hour ago. I had gotten up, showered, dressed, prepared breakfast and school lunches, ran to school drop-off, and returned home, a bit of a wreck with a few minutes to spare. I look down at my watch.
Fierce Pharma
NOVEMBER 8, 2024
AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and improper collection of patient data. | AstraZeneca confirmed its China president has been detained by Chinese authorities. Pfizer plans to invest $1 billion in China in the next five years. Sun Pharma's JAK inhibitor Leqselvi was slapped with an injunction in a lawsuit with Incyte.
STAT
NOVEMBER 8, 2024
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We expect to continue the never-ending quest to manicure the Pharmalot grounds, promenade with the official mascots, and catch up on napping. We also hope to hold another listening party, where the rotation will likely include this , this , this , this and this.
Fierce Healthcare
NOVEMBER 8, 2024
LAS VEGAS — Employers' healthcare costs continue to rise, leading them to seek new alternatives to drive down expenses while avoiding steps to shift additional costs to workers. | In response to rising costs, some in the industry have been beating the drum for individual coverage health reimbursement arrangements, or ICHRA.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
NOVEMBER 8, 2024
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. If you’re in the market for a heartwarming story, look no further than this “real life rom com ” as related on Threads. (My heart, like the person who posted it, is about to burst).
pharmaphorum
NOVEMBER 8, 2024
Wales has extended a scheme to harness the power of genomics to improve cancer care and prevention via an alliance with gene-sequencing giant Illumina.
Fierce Pharma
NOVEMBER 8, 2024
Common oral medicines that have been used for decades as decongestants such as Sudafed, NyQuil and Benadryl may soon be cleared from shelves as the FDA has
pharmaphorum
NOVEMBER 8, 2024
Daiichi Sankyo signs a $300m deal with Alteogen to develop a subcutaneous version of anti-HER2 cancer drug Enhertu.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Fierce Pharma
NOVEMBER 8, 2024
After a positive phase 3 trial, Johnson & Johnson hopes its Darzalex could become the first treatment option for patients with smoldering multiple myeloma, an early-stage form of the blood diso | After a positive phase 3 trial, Johnson & Johnson hopes its Darzalex could become the first treatment option for patients with smoldering multiple myeloma, an early-stage form of the blood disorder.
Pharmaceutical Technology
NOVEMBER 8, 2024
A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its primary endpoint.
Fierce Pharma
NOVEMBER 8, 2024
Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that AstraZeneca and Amgen's Tezspire provided a statistically significant and clinically meaningful reduction in polyp size and nasal congestion in patients with severe chronic rhinosinusitis with nasal polyps.
Pharmacy Times
NOVEMBER 8, 2024
Tripp Logan, PharmD, reflects on being named Independent Pharmacist of the Year from the National Community Pharmacists Association.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
STAT
NOVEMBER 8, 2024
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.
Pharmaceutical Technology
NOVEMBER 8, 2024
The seemingly inexorable rise in global obesity is being reflected in the sales of diabetes and weight-loss drugs, including Ozempic.
pharmaphorum
NOVEMBER 8, 2024
The UK is squandering the vast resource of NHS patient data because too many obstacles are being placed in front of researchers trying to tap into it – holding back medical advances. That is the conclusion of the much-anticipated Sudlow Review – carried out by Prof Cathie Sudlow, chief scientist of Health Data Research (HDR) UK – which found that accessing patient data can take months or even years, hampering research into areas like dementia, cancer and heart disease.
Pharmacy Times
NOVEMBER 8, 2024
The demanding nature of pharmacy programs often leaves little time for self-care, social activities, or hobbies, leading to an imbalance that can foster burnout.
Fierce Pharma
NOVEMBER 8, 2024
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), following a string of exits by companies including Pfizer, UCB, WuXi AppTec and | The company opted not to renew its membership for 2025 following an annual review of its trade group associations, a spokesperson said.
Pharmaceutical Technology
NOVEMBER 8, 2024
Leqembi is approved for Alzheimer’s patients in multiple territories, but questions remain over its cost-effectiveness.
PharmaVoice
NOVEMBER 8, 2024
Past comments hint at the changes Robert F. Kennedy Jr. could make across the various sectors of healthcare.
Pharmacy Times
NOVEMBER 8, 2024
Off-label semaglutide has been linked to serious adverse effects, calling for increased regulation around compounding.
Drug Topics
NOVEMBER 8, 2024
A new study found that individuals who received a COVID-19 vaccine more recently were less likely to develop long COVID.
Pharmacy Times
NOVEMBER 8, 2024
Panelists discuss how pharmacists actively engage in educating and coordinating with nurses, oncologists, and other health care providers by conducting in-service trainings, participating in multidisciplinary team meetings, and collaborating on the development and implementation of formularies, order sets, and treatment protocols to ensure optimal patient care in multiple myeloma management.
Fierce Pharma
NOVEMBER 8, 2024
With Indivior’s stock price in freefall over the past year, one of the company’s top investors is taking leadership to task, accusing the firm behind the opioid addiction treatment Sublocade of “ig | Investment fund Oaktree Capital Management has called for a shakeup of Indivior’s board of directors, referring to the more than 50% stock price drop Indivior has suffered in 2024 as “unacceptable.
Pharmacy Times
NOVEMBER 8, 2024
Panelists discuss how treatment regimens for multiple myeloma patients can be personalized to improve adherence and quality of life by considering factors such as dosing schedules and routes of administration while emphasizing the role of pharmacists in providing resources and support to keep patients informed, engaged, and compliant with their individualized treatment plans.
pharmaphorum
NOVEMBER 8, 2024
Conducting a cybersecurity audit on your pharmaceutical supply chain is crucial for protecting sensitive data. Learn how to properly assess and strengthen your cybersecurity measures with this guide.
Pharmacy Times
NOVEMBER 8, 2024
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Fierce Healthcare
NOVEMBER 8, 2024
The U.S. faces a critical shortage of primary care physicians, and the labor crunch is projected to get worse. | The company is working with New Mexico-based Presbyterian Healthcare Services to pilot its primary care AI pilot.
Expert insights. Personalized for you.
132 
Let's personalize your content